Dianthus Therapeutics Announces 2024 Annual Meeting of Stockholders on May 23
Ticker: DNTH · Form: DEF 14A · Filed: Apr 11, 2024 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | DEF 14A |
| Filed Date | Apr 11, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Auditor Ratification
TL;DR
<b>Dianthus Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, to elect directors, vote on executive compensation, approve an incentive plan, and ratify auditor appointment.</b>
AI Summary
Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. The 2024 Annual Meeting of Stockholders for Dianthus Therapeutics, Inc. will be held virtually on May 23, 2024, at 9:00 a.m. Eastern Time. Key agenda items include the election of two Class III directors, Leon O. Moulder, Jr. and Alison F. Lawton, for terms until the 2027 annual meeting. Stockholders will vote on an advisory basis to approve executive compensation and to determine the frequency of future advisory votes on executive compensation. The meeting will also cover the approval of an amendment and restatement of the Amended and Restated Dianthus Therapeutics, Inc. Stock Option and Incentive Plan. The appointment of Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified.
Why It Matters
For investors and stakeholders tracking Dianthus Therapeutics, Inc. /DE/, this filing contains several important signals. The meeting provides a platform for stockholders to directly influence corporate governance by electing directors and approving compensation practices. Key decisions regarding the company's long-term incentive structure and auditor independence are on the agenda, impacting future financial reporting and employee motivation.
Risk Assessment
Risk Level: low — Dianthus Therapeutics, Inc. /DE/ shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the director nominees and executive compensation proposals to make informed voting decisions at the upcoming annual meeting.
Key Numbers
- May 23, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders)
- 9:00 a.m. Eastern Time — Annual Meeting Time (2024 Annual Meeting of Stockholders)
- April 1, 2024 — Record Date (Stockholders of record on this date are entitled to vote)
- 2027 — Director Term End (Elected directors will serve until the 2027 annual meeting)
- December 31, 2024 — Fiscal Year End (Fiscal year for which auditor is appointed)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Leon O. Moulder, Jr. (person) — Director nominee
- Alison F. Lawton (person) — Director nominee
- Deloitte & Touche, LLP (company) — Independent registered public accounting firm
- May 23, 2024 (date) — Date of Annual Meeting
- April 1, 2024 (date) — Record date for voting
- 2027 (date) — Term for elected directors
- December 31, 2024 (date) — Fiscal year end for auditor appointment
FAQ
When did Dianthus Therapeutics, Inc. /DE/ file this DEF 14A?
Dianthus Therapeutics, Inc. /DE/ filed this Proxy Statement (DEF 14A) with the SEC on April 11, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Dianthus Therapeutics, Inc. /DE/ (DNTH).
Where can I read the original DEF 14A filing from Dianthus Therapeutics, Inc. /DE/?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Dianthus Therapeutics, Inc. /DE/.
What are the key takeaways from Dianthus Therapeutics, Inc. /DE/'s DEF 14A?
Dianthus Therapeutics, Inc. /DE/ filed this DEF 14A on April 11, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Dianthus Therapeutics, Inc. will be held virtually on May 23, 2024, at 9:00 a.m. Eastern Time.. Key agenda items include the election of two Class III directors, Leon O. Moulder, Jr. and Alison F. Lawton, for terms until the 2027 annual meeting.. Stockholders will vote on an advisory basis to approve executive compensation and to determine the frequency of future advisory votes on executive compensation..
Is Dianthus Therapeutics, Inc. /DE/ a risky investment based on this filing?
Based on this DEF 14A, Dianthus Therapeutics, Inc. /DE/ presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Dianthus Therapeutics, Inc. /DE/'s DEF 14A?
Stockholders should review the director nominees and executive compensation proposals to make informed voting decisions at the upcoming annual meeting. The overall sentiment from this filing is neutral.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
- Virtual Meeting Logistics [low — operational]: Ensuring a smooth and accessible virtual meeting experience for all stockholders is crucial for participation and engagement.
- Stock Option and Incentive Plan Approval [low — financial]: The amendment and restatement of the stock option and incentive plan requires stockholder approval and impacts future equity-based compensation.
Key Dates
- 2024-05-23: 2024 Annual Meeting of Stockholders — Key decisions on directors, compensation, and plans will be made.
- 2024-04-01: Record Date — Determines which stockholders are eligible to vote at the annual meeting.
Filing Stats: 4,612 words · 18 min read · ~15 pages · Grade level 12.2 · Accepted 2024-04-11 16:05:49
Key Financial Figures
- $0.001 — 6 shares of our common stock, par value $0.001 per share, outstanding on April 1, 2024
- $25,000 — terials and solicitation of votes for a $25,000 fee, plus reasonable out-of-pocket expe
Filing Documents
- dnth_2024_proxy.htm (DEF 14A) — 1125KB
- img265452752_0.jpg (GRAPHIC) — 33KB
- img265452752_1.jpg (GRAPHIC) — 6KB
- img265452752_2.jpg (GRAPHIC) — 33KB
- img265452752_3.jpg (GRAPHIC) — 48KB
- img265452752_4.jpg (GRAPHIC) — 310KB
- img265452752_5.jpg (GRAPHIC) — 179KB
- 0000950170-24-043693.txt ( ) — 1959KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 17 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 25
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANGEMENT 29 INFORMATION ABOUT OUR INDEPENDENT ACCOUNTANTS 33 REPORT OF THE AUDIT COMMITTEE 35 PROPOSAL NO. 1 – ELECTION OF CLASS III DIRECTORS 36 PROPOSAL NO. 2 – ADVISORY VOTE ON EXECUTIVE COMPENSATION 37 PROPOSAL NO. 3 – ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON EXECUTIVE COMPENSATION 38 PROPOSAL NO. 4 – AMENDMENT AND RESTATEMENT OF THE AMENDED AND RESTATED DIANTHUS THERAPEUTICS, INC. STOCK OPTION AND INCENTIVE PLAN 39 PROPOSAL NO. 5 – RATIFICATION OF THE APPOINTMENT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 46 STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS FOR NEXT YEAR'S ANNUAL MEETING 47 OTHER MATTERS 47 ANNEX A - SECOND AMENDED AND RESTATED DIANTHUS THERAPEUTICS, INC. STOCK OPTION AND INCENTIVE PLAN A-1 Table of Contents LEGAL MATTERS Forward-Looking Statements. This proxy statement may contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements other than statements of historical fact included in this proxy statement, including statements about the Company’s Board of Directors, corporate governance practices, executive compensation program, equity compensation utilization and environment, social and governance initiatives, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” &